Bullish
$SESN I'm really curious to see if we can undercut Adstilidtin in pricing to gain market share. Seems like treatment cost is a huge factor for usage and uptake of Ketruda, and I know that gene therapies like Adstilidtin are expensive and sensitive to storage conditions. Bladder cancer is already the most expensive cancer to treat, so I hope that our novel mechanism and simple manufacturing can help Sesen bring Vicinium to market cheaply so that way payers and patients can get an effective treatment at low cost.
  • 6
  • 1